Association between CYP17 polymorphisms and the development of breast cancer

CTRC-AACR San Antonio Breast Cancer Symposium

Cancer Health Disparities Conference 2009

Association between CYP17 polymorphisms and the development of breast cancer

KJ Helzlsouer, HY Huang, PT Strickland, S Hoffman, AJ Alberg, GW Comstock and DA Bell
Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205, USA.

A nested case-control study was conducted to determine whether a genetic polymorphism in the CYP17 gene, which encodes for an enzyme that mediates steroid hormone metabolism, was associated with an increased risk of breast cancer. No association was found between the presence of an A2 allele and the subsequent development of breast cancer [A1/A2 odds ratio, 0.61 (95% confidence interval, 0.33-1.14); A2/A2 odds ratio, 0.89 (95% confidence interval, 0.41-1.95)]. No significant association was observed with risk factors presumed to be surrogates for endogenous estrogen exposure, nor was there an association observed with the stage of disease at diagnosis. Genotype frequencies in this Caucasian population were similar to those reported for African-American, Asian, and Latino women. Additional studies of larger size are needed to achieve a consensus regarding the relevance of CYP17 genotypes to the risk of developing breast cancer.

This article has been cited by other articles:

Bibliography of Peer-Reviewed Journal Articles
Am. J. Epidemiol., August 20, 2008; (2008) kwn247v1.
[PDF]

M. Henningson, U. Johansson, A. Borg, H. Olsson, and H. Jernstrom
CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women
Mol. Hum. Reprod., April 1, 2007; 13(4): 231 - 236.
[Abstract] [Full Text] [PDF]

R. Piller, E. Verla-Tebit, S. Wang-Gohrke, J. Linseisen, and J. Chang-Claude
CYP17 Genotype Modifies the Association between Lignan Supply and Premenopausal Breast Cancer Risk in Humans
J. Nutr., June 1, 2006; 136(6): 1596 - 1603.
[Abstract] [Full Text] [PDF]

N. C. Onland-Moret, C. H. van Gils, M. Roest, D. E. Grobbee, and P. H.M. Peeters
Cyp17, Urinary Sex Steroid Levels and Breast Cancer Risk in Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 815 - 820.
[Abstract] [Full Text] [PDF]

H. S. Kok, N. C. Onland-Moret, K. M. van Asselt, C. H. van Gils, Y. T. van der Schouw, D. E. Grobbee, and P. H.M. Peeters
No association of estrogen receptor {alpha} and cytochrome P450c17{alpha} polymorphisms with age at menopause in a Dutch cohort
Hum. Reprod., February 1, 2005; 20(2): 536 - 542.
[Abstract] [Full Text] [PDF]

B. K. Dunn, D. L. Wickerham, and L. G. Ford
Prevention of Hormone-Related Cancers: Breast Cancer
J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367.
[Abstract] [Full Text] [PDF]

L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little
CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review
Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740.
[Abstract] [Full Text] [PDF]

F. Sata, H. Yamada, A. Yamada, E. H. Kato, S. Kataoka, Y. Saijo, T. Kondo, J. Tamaki, H. Minakami, and R. Kishi
A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss
Mol. Hum. Reprod., November 1, 2003; 9(11): 725 - 728.
[Abstract] [Full Text] [PDF]

S. E. McCann, K. B. Moysich, J. L. Freudenheim, C. B. Ambrosone, and P. G. Shields
The Risk of Breast Cancer Associated with Dietary Lignans Differs by CYP17 Genotype in Women
J. Nutr., October 1, 2002; 132(10): 3036 - 3041.
[Abstract] [Full Text] [PDF]

H. S. Feigelson, R. McKean-Cowdin, and B. E. Henderson
Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis
Mutagenesis, September 1, 2002; 17(5): 445 - 446.
[Full Text] [PDF]

Z. Ye and J. M. Parry
Concerning the CYP17 MSPA1 polymorphism and breast cancer risk: a meta-analysis
Mutagenesis, September 1, 2002; 17(5): 447 - 448.
[Full Text] [PDF]

E. I. O. Garner, E. E. Stokes, R. S. Berkowitz, S. C. Mok, and D. W. Cramer
Polymorphisms of the Estrogen-metabolizing Genes CYP17 and Catechol-O-methyltransferase and Risk of Epithelial Ovarian Cancer
Cancer Res., June 1, 2002; 62(11): 3058 - 3062.
[Abstract] [Full Text] [PDF]

N. Kado, J. Kitawaki, H. Obayashi, H. Ishihara, H. Koshiba, I. Kusuki, K. Tsukamoto, G. Hasegawa, N. Nakamura, T. Yoshikawa, et al.
Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women
Hum. Reprod., April 1, 2002; 17(4): 897 - 902.
[Abstract] [Full Text] [PDF]

M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility
J. Med. Genet., April 1, 2002; 39(4): 225 - 242.
[Abstract] [Full Text] [PDF]

Z. Ye and J. M. Parry
The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis
Mutagenesis, March 1, 2002; 17(2): 119 - 126.
[Abstract] [Full Text] [PDF]

K. Armstrong
Genetic Susceptibility to Breast Cancer: From the Roll of the Dice to the Hand Women Were Dealt
JAMA, June 13, 2001; 285(22): 2907 - 2909.
[Full Text] [PDF]

M. T. Goodman, K. McDuffie, C. Guo, K. Terada, and T. A. Donlon
CYP17 Genotype and Ovarian Cancer: A Null Case-Control Study
Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 563 - 564.
[Full Text]

M. Clemons and P. Goss
Estrogen and the Risk of Breast Cancer
N. Engl. J. Med., January 25, 2001; 344(4): 276 - 285.
[Full Text] [PDF]

H. S. Feigelson, R. McKean-Cowdin, G. A. Coetzee, D. O. Stram, L. N. Kolonel, and B. E. Henderson
Building a Multigenic Model of Breast Cancer Susceptibility: CYP17 and HSD17B1 Are Two Important Candidates
Cancer Res., January 1, 2001; 61(2): 785 - 789.
[Abstract] [Full Text]

K. Mitrunen, N. Jourenkova, V. Kataja, M. Eskelinen, V.-M. Kosma, S. Benhamou, H. Vainio, M. Uusitupa, and A. Hirvonen
Steroid Metabolism Gene CYP17 Polymorphism and the Development of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1343 - 1348.
[Abstract] [Full Text]

A. B. Spurdle, J. L. Hopper, G. S. Dite, X. Chen, J. Cui, M. R. E. McCredie, G. G. Giles, M. C. Southey, D. J. Venter, D. F. Easton, et al.
CYP17 Promoter Polymorphism and Breast Cancer in Australian Women Under Age Forty Years
J Natl Cancer Inst, October 18, 2000; 92(20): 1674 - 1681.
[Abstract] [Full Text] [PDF]

T. Habuchi, Z. Liqing, T. Suzuki, R. Sasaki, N. Tsuchiya, H. Tachiki, N. Shimoda, S. Satoh, K. Sato, Y. Kakehi, et al.
Increased Risk of Prostate Cancer and Benign Prostatic Hyperplasia Associated with a CYP17 Gene Polymorphism with a Gene Dosage Effect
Cancer Res., October 1, 2000; 60(20): 5710 - 5713.
[Abstract] [Full Text]

P. A. Thompson and C. Ambrosone
Chapter 7: Molecular Epidemiology of Genetic Polymorphisms in Estrogen Metabolizing Enzymes in Human Breast Cancer
J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 125 - 134.
[Abstract] [Full Text] [PDF]

B. E. Henderson and H. S. Feigelson
Hormonal carcinogenesis
Carcinogenesis, March 1, 2000; 21(3): 427 - 433.
[Abstract] [Full Text] [PDF]

S. S. Coughlin and M. Piper
Genetic Polymorphisms and Risk of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 1999; 8(11): 1023 - 1032.
[Full Text]

A. M. Dunning, C. S. Healey, P. D. P. Pharoah, M. D. Teare, B. A. J. Ponder, and D. F. Easton
A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., October 1, 1999; 8(10): 843 - 854.
[Abstract] [Full Text]

R. M. Lunn, D. A. Bell, J. L. Mohler, and J. A. Taylor
Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
Carcinogenesis, September 1, 1999; 20(9): 1727 - 1731.
[Abstract] [Full Text] [PDF]

H. S. Feigelson, R. McKean-Cowdin, M. C. Pike, G. A. Coetzee, L. N. Kolonel, A. M. Y. Nomura, L. L. Marchand, and B. E. Henderson
Cytochrome P450c17{{alpha}} Gene (CYP17) Polymorphism Predicts Use of Hormone Replacement Therapy
Cancer Res., August 1, 1999; 59(16): 3908 - 3910.
[Abstract] [Full Text] [PDF]

V. N. Kristensen, E. K. Haraldsen, K. B. Anderson, P. E. Lonning, B. Erikstein, R. Karesen, O. S. Gabrielsen, and A.-L. Borresen-Dale
CYP17 and Breast Cancer Risk: The Polymorphism in the 5' Flanking Area of the Gene Does Not Influence Binding to Sp-1
Cancer Res., June 1, 1999; 59(12): 2825 - 2828.
[Abstract] [Full Text] [PDF]

C. A. Haiman, S. E. Hankinson, D. Spiegelman, G. A. Colditz, W. C. Willett, F. E. Speizer, K. T. Kelsey, and D. J. Hunter
The Relationship between a Polymorphism in CYP17 with Plasma Hormone Levels and Breast Cancer
Cancer Res., March 1, 1999; 59(5): 1015 - 1020.
[Abstract] [Full Text] [PDF]

Cancer Research	Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention	Molecular Cancer Therapeutics
Molecular Cancer Research	Cancer Prevention Research
Cancer Prevention Journals Portal	Cancer Reviews Online
Annual Meeting Education Book	Meeting Abstracts Online

Cancer Research	Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention	Molecular Cancer Therapeutics
Molecular Cancer Research	Cancer Prevention Research
Cancer Prevention Journals Portal	Cancer Reviews Online
Annual Meeting Education Book	Meeting Abstracts Online

				M. Henningson, U. Johansson, A. Borg, H. Olsson, and H. Jernstrom CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women Mol. Hum. Reprod., April 1, 2007; 13(4): 231 - 236. [Abstract] [Full Text] [PDF]

				R. Piller, E. Verla-Tebit, S. Wang-Gohrke, J. Linseisen, and J. Chang-Claude CYP17 Genotype Modifies the Association between Lignan Supply and Premenopausal Breast Cancer Risk in Humans J. Nutr., June 1, 2006; 136(6): 1596 - 1603. [Abstract] [Full Text] [PDF]

				N. C. Onland-Moret, C. H. van Gils, M. Roest, D. E. Grobbee, and P. H.M. Peeters Cyp17, Urinary Sex Steroid Levels and Breast Cancer Risk in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 815 - 820. [Abstract] [Full Text] [PDF]

				H. S. Kok, N. C. Onland-Moret, K. M. van Asselt, C. H. van Gils, Y. T. van der Schouw, D. E. Grobbee, and P. H.M. Peeters No association of estrogen receptor {alpha} and cytochrome P450c17{alpha} polymorphisms with age at menopause in a Dutch cohort Hum. Reprod., February 1, 2005; 20(2): 536 - 542. [Abstract] [Full Text] [PDF]

				B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]

				L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740. [Abstract] [Full Text] [PDF]

				F. Sata, H. Yamada, A. Yamada, E. H. Kato, S. Kataoka, Y. Saijo, T. Kondo, J. Tamaki, H. Minakami, and R. Kishi A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss Mol. Hum. Reprod., November 1, 2003; 9(11): 725 - 728. [Abstract] [Full Text] [PDF]

				S. E. McCann, K. B. Moysich, J. L. Freudenheim, C. B. Ambrosone, and P. G. Shields The Risk of Breast Cancer Associated with Dietary Lignans Differs by CYP17 Genotype in Women J. Nutr., October 1, 2002; 132(10): 3036 - 3041. [Abstract] [Full Text] [PDF]

				H. S. Feigelson, R. McKean-Cowdin, and B. E. Henderson Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, September 1, 2002; 17(5): 445 - 446. [Full Text] [PDF]

				Z. Ye and J. M. Parry Concerning the CYP17 MSPA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, September 1, 2002; 17(5): 447 - 448. [Full Text] [PDF]

				E. I. O. Garner, E. E. Stokes, R. S. Berkowitz, S. C. Mok, and D. W. Cramer Polymorphisms of the Estrogen-metabolizing Genes CYP17 and Catechol-O-methyltransferase and Risk of Epithelial Ovarian Cancer Cancer Res., June 1, 2002; 62(11): 3058 - 3062. [Abstract] [Full Text] [PDF]

				N. Kado, J. Kitawaki, H. Obayashi, H. Ishihara, H. Koshiba, I. Kusuki, K. Tsukamoto, G. Hasegawa, N. Nakamura, T. Yoshikawa, et al. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women Hum. Reprod., April 1, 2002; 17(4): 897 - 902. [Abstract] [Full Text] [PDF]

				M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility J. Med. Genet., April 1, 2002; 39(4): 225 - 242. [Abstract] [Full Text] [PDF]

				Z. Ye and J. M. Parry The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, March 1, 2002; 17(2): 119 - 126. [Abstract] [Full Text] [PDF]

				K. Armstrong Genetic Susceptibility to Breast Cancer: From the Roll of the Dice to the Hand Women Were Dealt JAMA, June 13, 2001; 285(22): 2907 - 2909. [Full Text] [PDF]

				M. T. Goodman, K. McDuffie, C. Guo, K. Terada, and T. A. Donlon CYP17 Genotype and Ovarian Cancer: A Null Case-Control Study Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 563 - 564. [Full Text]

				M. Clemons and P. Goss Estrogen and the Risk of Breast Cancer N. Engl. J. Med., January 25, 2001; 344(4): 276 - 285. [Full Text] [PDF]

				H. S. Feigelson, R. McKean-Cowdin, G. A. Coetzee, D. O. Stram, L. N. Kolonel, and B. E. Henderson Building a Multigenic Model of Breast Cancer Susceptibility: CYP17 and HSD17B1 Are Two Important Candidates Cancer Res., January 1, 2001; 61(2): 785 - 789. [Abstract] [Full Text]

				K. Mitrunen, N. Jourenkova, V. Kataja, M. Eskelinen, V.-M. Kosma, S. Benhamou, H. Vainio, M. Uusitupa, and A. Hirvonen Steroid Metabolism Gene CYP17 Polymorphism and the Development of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1343 - 1348. [Abstract] [Full Text]

				A. B. Spurdle, J. L. Hopper, G. S. Dite, X. Chen, J. Cui, M. R. E. McCredie, G. G. Giles, M. C. Southey, D. J. Venter, D. F. Easton, et al. CYP17 Promoter Polymorphism and Breast Cancer in Australian Women Under Age Forty Years J Natl Cancer Inst, October 18, 2000; 92(20): 1674 - 1681. [Abstract] [Full Text] [PDF]

ARTICLES

Association between CYP17 polymorphisms and the development of breast cancer

				T. Habuchi, Z. Liqing, T. Suzuki, R. Sasaki, N. Tsuchiya, H. Tachiki, N. Shimoda, S. Satoh, K. Sato, Y. Kakehi, et al. Increased Risk of Prostate Cancer and Benign Prostatic Hyperplasia Associated with a CYP17 Gene Polymorphism with a Gene Dosage Effect Cancer Res., October 1, 2000; 60(20): 5710 - 5713. [Abstract] [Full Text]

				P. A. Thompson and C. Ambrosone Chapter 7: Molecular Epidemiology of Genetic Polymorphisms in Estrogen Metabolizing Enzymes in Human Breast Cancer J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 125 - 134. [Abstract] [Full Text] [PDF]

				B. E. Henderson and H. S. Feigelson Hormonal carcinogenesis Carcinogenesis, March 1, 2000; 21(3): 427 - 433. [Abstract] [Full Text] [PDF]

				S. S. Coughlin and M. Piper Genetic Polymorphisms and Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 1999; 8(11): 1023 - 1032. [Full Text]

				A. M. Dunning, C. S. Healey, P. D. P. Pharoah, M. D. Teare, B. A. J. Ponder, and D. F. Easton A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 1999; 8(10): 843 - 854. [Abstract] [Full Text]

				R. M. Lunn, D. A. Bell, J. L. Mohler, and J. A. Taylor Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2) Carcinogenesis, September 1, 1999; 20(9): 1727 - 1731. [Abstract] [Full Text] [PDF]

				H. S. Feigelson, R. McKean-Cowdin, M. C. Pike, G. A. Coetzee, L. N. Kolonel, A. M. Y. Nomura, L. L. Marchand, and B. E. Henderson Cytochrome P450c17{{alpha}} Gene (CYP17) Polymorphism Predicts Use of Hormone Replacement Therapy Cancer Res., August 1, 1999; 59(16): 3908 - 3910. [Abstract] [Full Text] [PDF]

				V. N. Kristensen, E. K. Haraldsen, K. B. Anderson, P. E. Lonning, B. Erikstein, R. Karesen, O. S. Gabrielsen, and A.-L. Borresen-Dale CYP17 and Breast Cancer Risk: The Polymorphism in the 5' Flanking Area of the Gene Does Not Influence Binding to Sp-1 Cancer Res., June 1, 1999; 59(12): 2825 - 2828. [Abstract] [Full Text] [PDF]

				C. A. Haiman, S. E. Hankinson, D. Spiegelman, G. A. Colditz, W. C. Willett, F. E. Speizer, K. T. Kelsey, and D. J. Hunter The Relationship between a Polymorphism in CYP17 with Plasma Hormone Levels and Breast Cancer Cancer Res., March 1, 1999; 59(5): 1015 - 1020. [Abstract] [Full Text] [PDF]